Drug intelligence / Profile preview

GW-813893

Development stage: Phase 2
Lead developer: GSK
Modality: Small Molecules
Administration: Oral

Overview

GW‑813893 is a potent, selective, and orally active small molecule inhibitor of factor Xa, developed as an anticoagulant for the prevention and treatment of thromboembolic disorders such as venous thromboembolism. Its mechanism of action involves direct binding to the active site of factor Xa, thereby preventing the conversion of prothrombin to thrombin and inhibiting downstream coagulation processes. The drug was initially developed by GSK for cardiovascular indications but development was discontinued after reaching phase 2 clinical trials[3][5][6][7].

Other names: 478644-12-1CHEMBL220050CHEMBL-220050CHEMBL 220050UNII-1Y3JD5PEMSUNII1Y3JD5PEMSUNII 1Y3JD5PEMS2-(5-Chloro-2-Thienyl)-N-{(3s)-1-[(1s)-1-Methyl-2-Morpholin-4-Yl-2-Oxoethyl]-2-Oxopyrrolidin-3-Yl}ethenesulfonamide

Targets

F10 (Factor Xa)

Beyond the preview

Go deeper on GW-813893.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on GW-813893.

Explore the full profile